Toll-like Receptor 3D structures: Difference between revisions
Michal Harel (talk | contribs) No edit summary |
Michal Harel (talk | contribs) No edit summary |
||
| Line 4: | Line 4: | ||
{{#tree:id=OrganizedByTopic|openlevels=0| | {{#tree:id=OrganizedByTopic|openlevels=0| | ||
*Toll-like receptor 1 | *Toll-like receptor 1; Domains – TIR 625-785; ligand-binding (LBD) 22-703; transmembrane 698-730 | ||
**[[1fyv]] – hTLR1 TIR domain – human<br /> | **[[1fyv]] – hTLR1 TIR domain – human<br /> | ||
**[[6nih]] - hTLR1/VLRB.61<br /> | |||
**[[2z7x]], [[2z81]], [[2z82]] – hTLR1/VLRB.61 + hTLR2/VLRB.61 + lipopeptide | **[[2z7x]], [[2z81]], [[2z82]] – hTLR1/VLRB.61 + hTLR2/VLRB.61 + lipopeptide | ||
| Line 15: | Line 16: | ||
**[[2z80]] – hTLR2/VLRB.61<br /> | **[[2z80]] – hTLR2/VLRB.61<br /> | ||
**[[3a79]] – hTLR2/VLRB.61 + hTLR6/VLRB.61 + lipopeptide<br /> | **[[3a79]] – hTLR2/VLRB.61 + hTLR6/VLRB.61 + lipopeptide<br /> | ||
**[[6nig]] – hTLR2/VLRB.61 + diprovocim<br /> | |||
**[[3a7b]] - mTLR2/VLRB.61 – mouse<br /> | **[[3a7b]] - mTLR2/VLRB.61 – mouse<br /> | ||
**[[3a7c]] - mTLR2/VLRB.61 + PE-DTPA<br /> | **[[3a7c]] - mTLR2/VLRB.61 + PE-DTPA<br /> | ||
| Line 21: | Line 23: | ||
*Toll-like receptor 3 | *Toll-like receptor 3 | ||
**[[1ziw]], [[2a0z]] – hTLR3 | **[[1ziw]], [[2a0z]] – hTLR3 LBD<br /> | ||
**[[5gs0]] – hTLR3 ectodomain + antibody<br /> | **[[5gs0]] – hTLR3 ectodomain + antibody<br /> | ||
**[[2mk9]], [[2mka]] – hTLR3 transmembrane domain - NMR <br /> | **[[2mk9]], [[2mka]] – hTLR3 transmembrane domain - NMR <br /> | ||
**[[3cig]] – mTLR3 | **[[3ulv]], [[3ulu]], [[5gs0]] – hTLR3 LBD + antibody<br /> | ||
**[[3ciy]] - mTLR3 | **[[3cig]] – mTLR3 LBD<br /> | ||
**[[3ciy]] - mTLR3 LBD + RNA<br /> | |||
*Toll-like receptor 4 | *Toll-like receptor 4 | ||
| Line 32: | Line 35: | ||
**[[3ul8]], [[3ul7]] – hTLR4/VLRB.61 (mutant)<br /> | **[[3ul8]], [[3ul7]] – hTLR4/VLRB.61 (mutant)<br /> | ||
**[[5nam]], [[5nao]] – hTLR4 transmembrane domain - NMR<br /> | **[[5nam]], [[5nao]] – hTLR4 transmembrane domain - NMR<br /> | ||
**[[3fxi]], [[4g8a]] - hTLR4 | **[[3fxi]], [[4g8a]] - hTLR4 LBD + lymphocyte antigen 96<br /> | ||
**[[3ula]] - hTLR4/VLRB.61 + lymphocyte antigen 96<br /> | **[[3ula]] - hTLR4/VLRB.61 + lymphocyte antigen 96<br /> | ||
**[[2z64]], [[2z65]], [[5ijc]], [[5ijd]], [[3vq1]], [[3vq2]] – mTLR4 | **[[2z64]], [[2z65]], [[5ijc]], [[5ijd]], [[3vq1]], [[3vq2]] – mTLR4 LBD + lymphocyte antigen 96<br /> | ||
*Toll-like receptor 5 | |||
**[[3j0a]] – hTLR5<br /> | |||
*Toll-like receptor 5B | *Toll-like receptor 5B | ||
| Line 41: | Line 48: | ||
**[[6bxa]] – zfTLR5B N-terminal + VLR2 <br /> | **[[6bxa]] – zfTLR5B N-terminal + VLR2 <br /> | ||
**[[6bxc]] – zfTLR5B N-terminal + VLR9 <br /> | **[[6bxc]] – zfTLR5B N-terminal + VLR9 <br /> | ||
**[[3v44]] – zfTLR5B/VLRB.61 <br /> | **[[3v44]], [[6bxa]], [[6bxc]] – zfTLR5B/VLRB.61 <br /> | ||
**[[3v47]] – zfTLR5B/VLRB.61 + flagellin<br /> | **[[3v47]] – zfTLR5B/VLRB.61 + flagellin<br /> | ||
| Line 50: | Line 57: | ||
*Toll-like receptor 7 | *Toll-like receptor 7 | ||
**[[5gmf]] – | **[[5gmf]] – moTLR7 + guanosine + poly-U - monkey <br /> | ||
**[[5gmg]] – | **[[5gmg]] – moTLR7 + loxoribine + poly-U <br /> | ||
**[[5gmh]] – | **[[5gmh]] – moTLR7 + resiquimod + poly-U <br /> | ||
*Toll-like receptor 8 | *Toll-like receptor 8 | ||
| Line 70: | Line 77: | ||
**[[3wpg]], [[3wph]], [[3wpi]] – mTLR9 + DNA <br /> | **[[3wpg]], [[3wph]], [[3wpi]] – mTLR9 + DNA <br /> | ||
**[[5zln]] – mTLR9 (mutant) + DNA <br /> | **[[5zln]] – mTLR9 (mutant) + DNA <br /> | ||
**[[4qdh]] – mTLR9/VLRB.61 <br /> | |||
*Toll-like receptor 10 | *Toll-like receptor 10 | ||